Kiniksa Pharmaceuticals Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $17.11
- Today's High:
- $17.68
- Open Price:
- $17.44
- 52W Low:
- $10.135
- 52W High:
- $20.65
- Prev. Close:
- $17.43
- Volume:
- 173023
Company Statistics
- Market Cap.:
- $1.25 billion
- Book Value:
- 5.881
- Revenue TTM:
- $280.84 million
- Operating Margin TTM:
- 13.57%
- Gross Profit TTM:
- $173.21 million
- Profit Margin:
- 82.35%
- Return on Assets TTM:
- 6.86%
- Return on Equity TTM:
- 81.84%
Company Profile
Kiniksa Pharmaceuticals Ltd had its IPO on 2018-05-24 under the ticker symbol KNSA.
The company operates in the Healthcare sector and Biotechnology industry. Kiniksa Pharmaceuticals Ltd has a staff strength of 220 employees.
Stock update
Shares of Kiniksa Pharmaceuticals Ltd opened at $17.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $17.11 - $17.68, and closed at $17.16.
This is a -1.55% slip from the previous day's closing price.
A total volume of 173,023 shares were traded at the close of the day’s session.
In the last one week, shares of Kiniksa Pharmaceuticals Ltd have slipped by -3.38%.
Kiniksa Pharmaceuticals Ltd's Key Ratios
Kiniksa Pharmaceuticals Ltd has a market cap of $1.25 billion, indicating a price to book ratio of 2.8247 and a price to sales ratio of 6.1425.
In the last 12-months Kiniksa Pharmaceuticals Ltd’s revenue was $280.84 million with a gross profit of $173.21 million and an EBITDA of $40.40 million. The EBITDA ratio measures Kiniksa Pharmaceuticals Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kiniksa Pharmaceuticals Ltd’s operating margin was 13.57% while its return on assets stood at 6.86% with a return of equity of 81.84%.
In Q2, Kiniksa Pharmaceuticals Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 165%.
Kiniksa Pharmaceuticals Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 5.3174
- PEG
Its diluted EPS in the last 12-months stands at $3.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kiniksa Pharmaceuticals Ltd’s profitability.
Kiniksa Pharmaceuticals Ltd stock is trading at a EV to sales ratio of 5.0309 and a EV to EBITDA ratio of -29.7518. Its price to sales ratio in the trailing 12-months stood at 6.1425.
Kiniksa Pharmaceuticals Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $-416656000.00
- Total Liabilities
- $47.47 million
- Operating Cash Flow
- $35.53 million
- Capital Expenditure
- $34000
- Dividend Payout Ratio
- 0%
Kiniksa Pharmaceuticals Ltd ended 2024 with $-416656000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $-416656000.00 while shareholder equity stood at $-489332000.00.
Kiniksa Pharmaceuticals Ltd ended 2024 with $0 in deferred long-term liabilities, $47.47 million in other current liabilities, 14000.00 in common stock, $-489332000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $112.57 million and cash and short-term investments were $184.99 million. The company’s total short-term debt was $2,238,000 while long-term debt stood at $0.
Kiniksa Pharmaceuticals Ltd’s total current assets stands at $184.99 million while long-term investments were $0 and short-term investments were $72.43 million. Its net receivables were $24.65 million compared to accounts payable of $648000.00 and inventory worth $23.96 million.
In 2024, Kiniksa Pharmaceuticals Ltd's operating cash flow was $35.53 million while its capital expenditure stood at $34000.
Comparatively, Kiniksa Pharmaceuticals Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $17.16
- 52-Week High
- $20.65
- 52-Week Low
- $10.135
- Analyst Target Price
- $22.25
Kiniksa Pharmaceuticals Ltd stock is currently trading at $17.16 per share. It touched a 52-week high of $20.65 and a 52-week low of $20.65. Analysts tracking the stock have a 12-month average target price of $22.25.
Its 50-day moving average was $16.78 and 200-day moving average was $14.46 The short ratio stood at 4.86 indicating a short percent outstanding of 0%.
Around 468% of the company’s stock are held by insiders while 9634.6% are held by institutions.
Frequently Asked Questions About Kiniksa Pharmaceuticals Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.